<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Approach to the patient with postmenopausal uterine bleeding</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Approach to the patient with postmenopausal uterine bleeding</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Approach to the patient with postmenopausal uterine bleeding</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Annekathryn Goodman, MD, MPH, MS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert L Barbieri, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Postmenopausal bleeding (PMB) refers to any uterine bleeding in a menopausal patient (other than the expected cyclic bleeding that occurs in patients taking combined [ie, estrogen-progestin], cyclic, postmenopausal hormone therapy). As PMB is the cardinal sign of endometrial carcinoma, all postmenopausal patients with unanticipated PMB should be evaluated for endometrial hyperplasia/carcinoma. More commonly, however, the cause of bleeding in such patients is the result of a benign condition, such as endometrial polyps or atrophy.</p><p>The etiologies and evaluation of postmenopausal patients with uterine bleeding, as well as patients near the end of the perimenopausal transition with abnormal uterine bleeding (AUB), will be reviewed here.</p><p>The evaluation and management of postmenopausal patients with a nonuterine source of vaginal bleeding, as well as premenopausal patients with AUB, are discussed separately. (See  <a class="medical medical_review" href="/d/html/5440.html" rel="external">"Causes of female genital tract bleeding"</a> and  <a class="medical medical_review" href="/d/html/3263.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">INCIDENCE</span><span class="headingEndMark"> — </span>PMB accounts for approximately 5 percent of office gynecology visits [<a href="#rid1">1</a>] and occurs in approximately 4 to 11 percent of postmenopausal patients [<a href="#rid2">2-5</a>].</p><p>The incidence appears to be inversely related to the time since menopause, with the likelihood of bleeding decreasing over time. In a prospective study including 271 Danish postmenopausal patients who completed a daily diary for one year, more patients experienced PMB after the first 12 months of amenorrhea following menopause compared with &gt;3 years after menopause (estimated incidence of bleeding 409 per 1000 versus 42 per 1000 person-years) [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H3"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>The differential diagnosis of bleeding in postmenopausal patients is less broad than that for abnormal bleeding in premenopausal patients since the various causes of anovulation are not relevant. In a prospective study including 454 postmenopausal patients with uterine bleeding, the frequency of endometrial pathology was as follows [<a href="#rid6">6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Polyp (37.7 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Hypotrophy/atrophy (30.8 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Proliferative/secretory (14.5 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Carcinoma (6.6 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Fibroid (6.2 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperplasia without atypia (2 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperplasia with atypia (0.2 percent)</p><p></p><p>By comparison, the background prevalence of endometrial pathology in postmenopausal patients without bleeding is lower. In two studies including gynecologically asymptomatic breast cancer patients prior to administration of adjuvant therapy, the baseline risk of an endometrial abnormality was 17 to 18 percent [<a href="#rid7">7,8</a>]. As with postmenopausal patients with bleeding, the most common abnormalities were atrophy and polyps.</p><p class="headingAnchor" id="H2566823762"><span class="h2">Structural abnormalities</span></p><p class="headingAnchor" id="H6"><span class="h3">Polyps</span><span class="headingEndMark"> — </span>Endometrial polyps are localized hyperplastic overgrowths of endometrial glands and stroma that are a common cause of perimenopausal and early postmenopausal bleeding. Growth of polyps can be stimulated by estrogen therapy or <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a>. While the majority of polyps are benign, the incidence of malignant or hyperplastic polyps is higher in postmenopausal compared with premenopausal patients. (See  <a class="medical medical_review" href="/d/html/5457.html" rel="external">"Endometrial polyps"</a>.)</p><p class="headingAnchor" id="H542181424"><span class="h3">Atrophy</span><span class="headingEndMark"> — </span>The hypoestrogenic changes that occur in menopause cause atrophy of the endometrium and vagina. In the uterus, the collapsed atrophic endometrial surfaces contain little or no fluid to prevent intracavitary friction [<a href="#rid9">9</a>]. This results in microerosions of the surface epithelium and a subsequent chronic inflammatory reaction (chronic endometritis), which is prone to light bleeding or spotting.</p><p>Hypoestrogenic changes of the labia, vagina, urethra, and bladder are described in detail separately. (See  <a class="medical medical_review" href="/d/html/5464.html" rel="external">"Genitourinary syndrome of menopause (vulvovaginal atrophy): Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H2775428081"><span class="h3">Leiomyomata uteri</span><span class="headingEndMark"> — </span>Benign leiomyomata uteri (fibroids) are the most common pelvic tumors in females; however, the prevalence in postmenopausal patients is one-tenth that of premenopausal patients [<a href="#rid10">10</a>]. While fibroids may cause heavy bleeding, bulk symptoms, or pain in the reproductive years, after menopause most fibroids will decrease in size. In addition, any PMB must be assumed to arise from endometrial pathology or atrophy, and not from the fibroid itself [<a href="#rid11">11</a>]. An exception are patients on hormone replacement therapy; such treatment may stimulate fibroid growth and increase withdrawal bleeding [<a href="#rid12">12</a>].</p><p>Although rare, the diagnosis of a uterine sarcoma should be considered in postmenopausal patients in whom a fibroid is increasing in size or producing symptoms (eg, pelvic pressure, pain, bleeding); while the incidence of sarcoma is higher in such patients, it is still small. (See  <a class="medical medical_review" href="/d/html/14203.html" rel="external">"Uterine fibroids (leiomyomas): Differentiating fibroids from uterine sarcomas"</a>.)</p><p class="headingAnchor" id="H4038531140"><span class="h3">Adenomyosis</span><span class="headingEndMark"> — </span>Adenomyosis is a benign histologic finding of the uterus in which endometrial glands infiltrate into the myometrial wall. While it can cause pain and menorrhagia during the reproductive years, symptomatic adenomyosis does not occur after menopause in the absence of postmenopausal hormone therapy. The diagnosis may be suspected by ultrasound or magnetic resonance imaging, but can only be confirmed by pathologic examination following hysterectomy [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/d/html/5489.html" rel="external">"Uterine adenomyosis"</a>.)</p><p class="headingAnchor" id="H2085327758"><span class="h2">Hyperplasia and carcinoma</span></p><p class="headingAnchor" id="H2018805443"><span class="h3">Endometrial hyperplasia</span><span class="headingEndMark"> — </span>Endometrial hyperplasia (EH; with or without atypia) may progress to, or coexist with, endometrial carcinoma, and often presents as uterine bleeding. EH is most common in perimenopausal or early postmenopausal patients; risk factors for EH are similar to those for endometrial carcinoma  (<a class="graphic graphic_table graphicRef62089" href="/d/graphic/62089.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/3217.html" rel="external">"Endometrial hyperplasia: Clinical features, diagnosis, and differential diagnosis"</a>.)</p><p class="headingAnchor" id="H4214831466"><span class="h3">Endometrial carcinoma</span><span class="headingEndMark"> — </span>Endometrial carcinoma is the fourth most common cancer in females in the United States; it is more common in postmenopausal compared with premenopausal patients and presents with vaginal bleeding in most patients [<a href="#rid14">14-18</a>]. In a meta-analysis including 92 studies and over 31,000 patients with PMB, the overall pooled risk of endometrial cancer was 9 percent; the risk was lower (6 percent) when only prospective or retrospective studies were included [<a href="#rid19">19</a>]. Subset analyses found higher rates of endometrial cancer in studies that excluded patients using menopausal hormone therapy (risk: 12 percent), and in patients with both PMB and a sonographic endometrial thickness ≥4 to 5 mm (risk: 19 percent; definition of a thickened endometrium varied across studies).</p><p>Increasing age, nulliparity, and diabetes mellitus are also associated with increased rates of endometrial carcinoma  (<a class="graphic graphic_table graphicRef62089" href="/d/graphic/62089.html" rel="external">table 1</a>) [<a href="#rid20">20,21</a>]. (See  <a class="medical medical_review" href="/d/html/3249.html" rel="external">"Endometrial carcinoma: Epidemiology, risk factors, and prevention"</a>.)</p><p>Choriocarcinoma as a cause of uterine bleeding in a postmenopausal patient has also been described [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H882065961"><span class="h3">Upper genital tract carcinomas</span><span class="headingEndMark"> — </span>PMB can be a symptom from carcinomas arising in the upper genital tract (ie, fallopian tubes). In a five-year review of fallopian and ovarian carcinomas treated at a major cancer center in the United Kingdom, of the eight patients diagnosed with primary fallopian tube carcinomas, six (75 percent) presented with PMB [<a href="#rid23">23</a>]. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/3238.html" rel="external">"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis", section on 'Vaginal bleeding'</a>.)</p><p class="headingAnchor" id="H3635352969"><span class="h2">Medications</span></p><p class="headingAnchor" id="H7"><span class="h3">Postmenopausal hormone therapy</span><span class="headingEndMark"> — </span>Uterine bleeding occurs in almost all patients receiving combined (ie, estrogen-progestin), cyclic hormone therapy. While uterine bleeding can also occur in the early months of combined, continuous hormone therapy regimens, patients with continued bleeding (eg, beyond six months) require endometrial evaluation. This is discussed in detail separately. (See <a class="local">'Evaluation of the endometrium'</a> below and  <a class="medical medical_review" href="/d/html/3232.html" rel="external">"Overview of the evaluation of the endometrium for malignant or premalignant disease", section on 'Patients on hormone therapy'</a> and  <a class="medical medical_review" href="/d/html/7450.html" rel="external">"Treatment of menopausal symptoms with hormone therapy", section on 'Side effects'</a>.)</p><p class="headingAnchor" id="H3380114904"><span class="h3">Other medications</span><span class="headingEndMark"> — </span>Use of certain medications (eg, anticoagulants, antiplatelet therapies), herbal preparations, and dietary supplements may interfere with primary or secondary hemostasis and result in uterine bleeding  (<a class="graphic graphic_table graphicRef120264" href="/d/graphic/120264.html" rel="external">table 2</a>). In large doses, soy and other phytoestrogens may also be associated with stimulation of the endometrial lining [<a href="#rid24">24</a>], polyp and leiomyoma growth [<a href="#rid25">25</a>], and increased rates of endometrial hyperplasia [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H83652408"><span class="h2">Other</span></p><p class="headingAnchor" id="H11"><span class="h3">Disease in adjacent organs</span><span class="headingEndMark"> — </span>Inflammation of adjacent organs, such as diverticulitis, can occasionally cause a corresponding inflammation of the female upper genital tract. Similarly, a ruptured sigmoid diverticulum may fistulize into the uterus and present as uterine bleeding, discharge, and endometritis. (See  <a class="medical medical_review" href="/d/html/2633.html" rel="external">"Clinical manifestations and diagnosis of acute colonic diverticulitis in adults", section on 'Fistula'</a>.)</p><p class="headingAnchor" id="H12"><span class="h3">Post radiation therapy</span><span class="headingEndMark"> — </span>Uterine bleeding can be a late effect of radiation therapy. Obliterative endarteritis and the vascular narrowing of aging and arteriosclerosis lead to devascularization of the radiated tissues. Tissue necrosis causes viscus perforation, tissue sloughing, and bleeding. Pelvic radiation therapy can also cause hemorrhagic cystitis, proctitis, and vaginal vault necrosis, and result in significant blood loss and pain. (See  <a class="medical medical_review" href="/d/html/90926.html" rel="external">"Treatment-related toxicity from the use of radiation therapy for gynecologic malignancies"</a>.)</p><p class="headingAnchor" id="H14"><span class="h3">Infection</span><span class="headingEndMark"> — </span>Endometritis is an uncommon cause of PMB. Genital tuberculosis may also present as PMB, however, this is a rare cause of PMB in resource-abundant countries [<a href="#rid27">27-30</a>]. (See  <a class="medical medical_review" href="/d/html/5462.html" rel="external">"Endometritis unrelated to pregnancy", section on 'Tuberculous endometritis'</a> and  <a class="medical medical_review" href="/d/html/8003.html" rel="external">"Urogenital tuberculosis", section on 'Genital tuberculosis'</a>.)</p><p class="headingAnchor" id="H2843578448"><span class="h1">DISTINGUISHING UTERINE FROM OTHER GENITAL TRACT BLEEDING</span><span class="headingEndMark"> — </span>While vaginal bleeding is often attributed to an intrauterine source, it may arise from disease at any anatomic site in the lower genital tract (eg, vulva, vagina, cervix), upper genital tract (eg, fallopian tubes, ovaries), or a nongynecologic site (eg, urethra, bladder, anus, bowel  (<a class="graphic graphic_table graphicRef74527" href="/d/graphic/74527.html" rel="external">table 3</a>)). (See  <a class="medical medical_review" href="/d/html/5440.html" rel="external">"Causes of female genital tract bleeding"</a>.)</p><p>Nonuterine bleeding may also be caused by a foreign body (eg, pessary), consensual sexual intercourse, or sexual assault. Atrophic changes in postmenopausal patients increases the risk for both lower genital lacerations and lacerations of the cervix [<a href="#rid31">31-33</a>].</p><p>A careful history and physical examination will often permit the distinction between uterine and vaginal bleeding. (See <a class="local">'History'</a> below and <a class="local">'Physical examination'</a> below.)</p><p class="headingAnchor" id="H506800431"><span class="h1">DIAGNOSTIC APPROACH</span></p><p class="headingAnchor" id="H15"><span class="h2">Initial evaluation</span><span class="headingEndMark"> — </span>The primary goal in the diagnostic evaluation of postmenopausal patients with uterine bleeding is to exclude malignancy since increasing age is a risk factor for endometrial carcinoma  (<a class="graphic graphic_table graphicRef62089" href="/d/graphic/62089.html" rel="external">table 1</a>). A secondary goal is to exclude other intraabdominal processes (eg, diverticular disease, infection, other malignancies) and nonuterine sources of bleeding.</p><p class="headingAnchor" id="H16"><span class="h3">History</span><span class="headingEndMark"> — </span>Important information that can be elicited from the patient's history includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>When did the bleeding start?</p><p class="bulletIndent1"><span class="glyph">●</span>Were there precipitating factors, such as trauma, intercourse, or intimate partner violence?</p><p class="bulletIndent1"><span class="glyph">●</span>What is the nature of the bleeding (eg, duration, quantity)?</p><p class="bulletIndent1"><span class="glyph">●</span>Are there any associated symptoms such as pain, fever, or changes in bladder or bowel function?</p><p class="bulletIndent1"><span class="glyph">●</span>Does the patient take any medications (eg, hormone replacement therapy, anticoagulants), or herbal or dietary supplements?</p><p class="bulletIndent1"><span class="glyph">●</span>Does the patient have a history of obesity or diabetes mellitus?</p><p class="bulletIndent1"><span class="glyph">●</span>Is there a family history of breast, colon, and endometrial cancer?</p><p></p><p>The answers to these questions may help direct the clinician toward one of the major categories of uterine bleeding (see <a class="local">'Etiology'</a> above). As an example, obesity, diabetes mellitus, and use of <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> are risk factors for endometrial cancer; vaginal dryness and soreness with dyspareunia and bleeding after intercourse suggest atrophy. By contrast, a history of trauma, sexual assault, or intimate partner violence, which is prevalent in postmenopausal and vulnerable (eg, nursing home) populations [<a href="#rid34">34</a>], may help direct the clinician toward a nonuterine source of bleeding.</p><p>Patients with uterine bleeding <strong>and</strong> cervical stenosis may present with pain rather than bleeding, as the egress of blood from the uterine cavity is inhibited and results in hematometra. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5440.html" rel="external">"Causes of female genital tract bleeding"</a> and  <a class="medical medical_review" href="/d/html/3316.html" rel="external">"Overview of endometrial ablation", section on 'Complications'</a>.)</p><p class="headingAnchor" id="H2038309657"><span class="h3">Physical examination</span><span class="headingEndMark"> — </span>A complete physical examination, including calculation of the patient's body mass index (BMI (<a class="calc calc_professional" href="/d/html/13478.html" rel="external">calculator 1</a>)) and examining the skin for ecchymosis or trauma, should be performed.</p><p>A pelvic examination is performed to help determine the bleeding site. The size and contour of the uterus, as well as tenderness (if present), as well as any suspicious lesions, lacerations, or foreign bodies should be noted; lower genital tract (eg, vulva, vagina, exocervix) causes of bleeding can usually be excluded by a normal physical examination.</p><p class="headingAnchor" id="H17"><span class="h3">Evaluation of the endometrium</span><span class="headingEndMark"> — </span>Either endometrial sampling or transvaginal ultrasound (TVUS) is used as the initial test for evaluating the endometrium. Endometrial biopsy is often preferred because it results in a tissue diagnosis and has a high sensitivity, low complication rate, and low cost. A detailed discussion of these tests for the evaluation of the endometrium can be found separately. (See  <a class="medical medical_review" href="/d/html/3232.html" rel="external">"Overview of the evaluation of the endometrium for malignant or premalignant disease"</a> and  <a class="medical medical_review" href="/d/html/3254.html" rel="external">"Endometrial sampling procedures"</a>.)</p><p class="headingAnchor" id="H18"><span class="h3">Evaluation of the cervix</span><span class="headingEndMark"> — </span>All patients with PMB need an evaluation for cervical cancer, as it can be difficult to distinguish between uterine and endocervical bleeding. Any visible lesions need to be biopsied, even if cervical cytology is normal. (See  <a class="medical medical_review" href="/d/html/3219.html" rel="external">"Cervical cancer screening tests: Techniques for cervical cytology and human papillomavirus testing"</a> and  <a class="medical medical_review" href="/d/html/3179.html" rel="external">"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H19"><span class="h2">Additional testing for select patients</span><span class="headingEndMark"> — </span>In postmenopausal patients, uterine bleeding is usually light and self-limited, and treatment is usually unnecessary once endometrial carcinoma (or premalignant histology) has been excluded.</p><p class="headingAnchor" id="H2474700137"><span class="h3">Patients with pathology on inital evaluation</span><span class="headingEndMark"> — </span>If pathology (eg, polyp, hyperplasia, malignancy) is found on initial evaluation, the patient is managed according to standard guidelines. (See  <a class="medical medical_review" href="/d/html/5457.html" rel="external">"Endometrial polyps", section on 'Management'</a> and  <a class="medical medical_review" href="/d/html/16723.html" rel="external">"Endometrial hyperplasia: Management and prognosis"</a> and  <a class="medical medical_review" href="/d/html/3251.html" rel="external">"Endometrial carcinoma: Staging and surgical treatment"</a>.)</p><p class="headingAnchor" id="H1828935435"><span class="h3">Patients with recurrent bleeding</span><span class="headingEndMark"> — </span>For patients with recurrent or persistent bleeding, further diagnostic evaluation (eg, dilation and curettage with hysteroscopy, <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> infusion sonography) is indicated. Persistent bleeding can be a sign of endometrial carcinoma, even in the setting of a "benign" endometrial biopsy or thin (ie, ≤4 mm) endometrial stripe on TVUS. (See <a class="local">'Evaluation of the endometrium'</a> above and  <a class="medical medical_review" href="/d/html/3232.html" rel="external">"Overview of the evaluation of the endometrium for malignant or premalignant disease", section on 'Postmenopausal patients with bleeding'</a>.)</p><p class="headingAnchor" id="H1261950614"><span class="h3">Patients with proliferative/secretory endometrium</span><span class="headingEndMark"> — </span>Proliferative/secretory endometrium is not a form of endometrial hyperplasia but suggests active estradiol secretion (eg, by adipose tissue; an estrogen-producing tumor) or exposure to exogenous estrogens and should be evaluated further. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/16723.html" rel="external">"Endometrial hyperplasia: Management and prognosis", section on 'Proliferative endometrium'</a>.)</p><p class="headingAnchor" id="H3857433436"><span class="h2">When to refer</span><span class="headingEndMark"> — </span>Referral to a gynecologist is appropriate for patients who have persistent bleeding, if there is suspicion of malignancy, if surgery (eg, dilation and curettage) is required, or if the primary care clinician is not comfortable performing endometrial sampling. If <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> infusion sonography or hysteroscopy is indicated and the initial clinician lacks the experience or resources to perform these procedures, referral to a gynecologist with the needed experience and equipment is also appropriate.</p><p class="headingAnchor" id="H4094867414"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109362.html" rel="external">"Society guideline links: Abnormal uterine bleeding"</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/8401.html" rel="external">"Patient education: Abnormal uterine bleeding (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H21"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Postmenopausal bleeding (PMB) refers to any uterine bleeding in a menopausal patient (other than the expected cyclic bleeding that occurs in patients taking combined [ie, estrogen-progestin], cyclic, postmenopausal hormone therapy). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Structural abnormalities</strong> – Endometrial polyps and atrophy are the most common causes of PMB; leiomyomata and adenomyosis should not cause PMB in the absence of postmenopausal hormone therapy. While polyps and leiomyomata are typically benign, malignancy can occur. (See <a class="local">'Structural abnormalities'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hyperplasia and carcinoma</strong> – Endometrial carcinoma is the cause of PMB in approximately 6 to 9 percent of patients overall. For patients who are not taking menopausal hormone therapy, the risk is higher (approximately 12 percent). PMB is also common in patients with endometrial hyperplasia. (See <a class="local">'Hyperplasia and carcinoma'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Medications</strong> – Uterine bleeding occurs in almost all patients receiving combined (ie, estrogen-progestin), cyclic hormone therapy; it is also common in the early months of continuous hormone therapy regimens. Other medications (eg, anticoagulants, antiplatelet therapies), herbal preparations, and dietary supplements may also result in uterine bleeding  (<a class="graphic graphic_table graphicRef120264" href="/d/graphic/120264.html" rel="external">table 2</a>). (See <a class="local">'Medications'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other</strong> – Inflammation of adjacent organs (eg, diverticulitis) and infection (eg, endometritis) are uncommon causes of PMB. (See <a class="local">'Other'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial evaluation</strong> – The primary goal in the diagnostic evaluation of postmenopausal patients with uterine bleeding is to exclude malignancy since increasing age is a risk factor endometrial carcinoma  (<a class="graphic graphic_table graphicRef62089" href="/d/graphic/62089.html" rel="external">table 1</a>). Either endometrial biopsy or transvaginal ultrasound (TVUS) is used as the initial test for evaluating the endometrium; in our practice, we typically perform endometrial biopsy due to its high sensitivity, low complication rate, and low cost. (See <a class="local">'Initial evaluation'</a> above and  <a class="medical medical_review" href="/d/html/3232.html" rel="external">"Overview of the evaluation of the endometrium for malignant or premalignant disease", section on 'Postmenopausal patients with bleeding'</a>.)</p><p></p><p class="bulletIndent1">A secondary goal is to exclude other intraabdominal processes (eg, diverticular disease, infection, other malignancies) and nonuterine sources of bleeding (eg, foreign body, trauma). (See <a class="local">'Disease in adjacent organs'</a> above and <a class="local">'Distinguishing uterine from other genital tract bleeding'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional testing</strong> – Uterine bleeding in postmenopausal patients is usually light and self-limited and treatment is usually unnecessary once cancer has been excluded. However, further diagnostic evaluation (eg, dilation and curettage with hysteroscopy, <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> infusion sonography) is indicated for recurrent or persistent bleeding as this can be a sign of endometrial carcinoma. (See <a class="local">'Additional testing for select patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Referral</strong> – Referral to a gynecologist is appropriate for patients who have persistent bleeding, if there is suspicion of malignancy, if surgery (eg, dilation and curettage) is required, or if the primary care clinician is not comfortable performing endometrial sampling. (See <a class="local">'When to refer'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Moodley M, Roberts C. Clinical pathway for the evaluation of postmenopausal bleeding with an emphasis on endometrial cancer detection. J Obstet Gynaecol 2004; 24:736.</a></li><li><a class="nounderline abstract_t">Astrup K, Olivarius Nde F. Frequency of spontaneously occurring postmenopausal bleeding in the general population. Acta Obstet Gynecol Scand 2004; 83:203.</a></li><li><a class="nounderline abstract_t">Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321.</a></li><li><a class="nounderline abstract_t">Smith-Bindman R, Weiss E, Feldstein V. How thick is too thick? When endometrial thickness should prompt biopsy in postmenopausal women without vaginal bleeding. Ultrasound Obstet Gynecol 2004; 24:558.</a></li><li><a class="nounderline abstract_t">Mirkin S, Archer DF, Taylor HS, et al. Differential effects of menopausal therapies on the endometrium. Menopause 2014; 21:899.</a></li><li><a class="nounderline abstract_t">Van den Bosch T, Ameye L, Van Schoubroeck D, et al. Intra-cavitary uterine pathology in women with abnormal uterine bleeding: a prospective study of 1220 women. Facts Views Vis Obgyn 2015; 7:17.</a></li><li><a class="nounderline abstract_t">Duffy S, Jackson TL, Lansdown M, et al. The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data. BJOG 2003; 110:1099.</a></li><li><a class="nounderline abstract_t">Berlière M, Radikov G, Galant C, et al. Identification of women at high risk of developing endometrial cancer on tamoxifen. Eur J Cancer 2000; 36 Suppl 4:S35.</a></li><li><a class="nounderline abstract_t">Ferenczy A. Pathophysiology of endometrial bleeding. Maturitas 2003; 45:1.</a></li><li><a class="nounderline abstract_t">Paramsothy P, Harlow SD, Greendale GA, et al. Bleeding patterns during the menopausal transition in the multi-ethnic Study of Women's Health Across the Nation (SWAN): a prospective cohort study. BJOG 2014; 121:1564.</a></li><li><a class="nounderline abstract_t">Ulin M, Ali M, Chaudhry ZT, et al. Uterine fibroids in menopause and perimenopause. Menopause 2020; 27:238.</a></li><li><a class="nounderline abstract_t">Moro E, Degli Esposti E, Borghese G, et al. The Impact of Hormonal Replacement Treatment in Postmenopausal Women with Uterine Fibroids: A State-of-the-Art Review of the Literature. Medicina (Kaunas) 2019; 55.</a></li><li><a class="nounderline abstract_t">Reinhold C, McCarthy S, Bret PM, et al. Diffuse adenomyosis: comparison of endovaginal US and MR imaging with histopathologic correlation. Radiology 1996; 199:151.</a></li><li><a class="nounderline abstract_t">Burbos N, Musonda P, Giarenis I, et al. Age-related differential diagnosis of vaginal bleeding in postmenopausal women: a series of 3047 symptomatic postmenopausal women. Menopause Int 2010; 16:5.</a></li><li><a class="nounderline abstract_t">Ronghe R, Gaudoin M. Women with recurrent postmenopausal bleeding should be re-investigated but are not more likely to have endometrial cancer. Menopause Int 2010; 16:9.</a></li><li><a class="nounderline abstract_t">van Hanegem N, Breijer MC, Khan KS, et al. Diagnostic evaluation of the endometrium in postmenopausal bleeding: an evidence-based approach. Maturitas 2011; 68:155.</a></li><li><a class="nounderline abstract_t">Prendergast EN, Misch E, Chou YA, et al. Insufficient endometrial biopsy results in women with abnormal uterine bleeding. Obstet Gynecol 2014; 123 Suppl 1:180S.</a></li><li><a class="nounderline abstract_t">Cote ML, Ruterbusch JJ, Ahmed Q, et al. Endometrial cancer in morbidly obese women: do racial disparities affect surgical or survival outcomes? Gynecol Oncol 2014; 133:38.</a></li><li><a class="nounderline abstract_t">Clarke MA, Long BJ, Del Mar Morillo A, et al. Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women: A Systematic Review and Meta-analysis. JAMA Intern Med 2018; 178:1210.</a></li><li><a class="nounderline abstract_t">Salman MC, Bozdag G, Dogan S, Yuce K. Role of postmenopausal bleeding pattern and women's age in the prediction of endometrial cancer. Aust N Z J Obstet Gynaecol 2013; 53:484.</a></li><li><a class="nounderline abstract_t">Munro MG, Southern California Permanente Medical Group’s Abnormal Uterine Bleeding Working Group. Investigation of women with postmenopausal uterine bleeding: clinical practice recommendations. Perm J 2014; 18:55.</a></li><li><a class="nounderline abstract_t">Marcu M, Chefani A, Sajin M. Postmenopausal choriocarcinoma: a case report. Rom J Morphol Embryol 2005; 46:145.</a></li><li><a class="nounderline abstract_t">Clayton NL, Jaaback KS, Hirschowitz L. Primary fallopian tube carcinoma - the experience of a UK cancer centre and a review of the literature. J Obstet Gynaecol 2005; 25:694.</a></li><li><a class="nounderline abstract_t">van Hunsel FP, Kampschöer P. [Postmenopausal bleeding and dietary supplements: a possible causal relationship with hop- and soy-containing preparations]. Ned Tijdschr Geneeskd 2012; 156:A5095.</a></li><li><a class="nounderline abstract_t">Chandrareddy A, Muneyyirci-Delale O, McFarlane SI, Murad OM. Adverse effects of phytoestrogens on reproductive health: a report of three cases. Complement Ther Clin Pract 2008; 14:132.</a></li><li><a class="nounderline abstract_t">Unfer V, Casini ML, Costabile L, et al. Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study. Fertil Steril 2004; 82:145.</a></li><li><a class="nounderline abstract_t">Sabadell J, Castellví J, Baró F. Tuberculous endometritis presenting as postmenopausal bleeding. Int J Gynaecol Obstet 2007; 96:203.</a></li><li><a class="nounderline abstract_t">Mengistu Z, Engh V, Melby KK, et al. Postmenopausal vaginal bleeding caused by endometrial tuberculosis. Acta Obstet Gynecol Scand 2007; 86:631.</a></li><li><a class="nounderline abstract_t">Güngördük K, Ulker V, Sahbaz A, et al. Postmenopausal tuberculosis endometritis. Infect Dis Obstet Gynecol 2007; 2007:27028.</a></li><li><a class="nounderline abstract_t">Garg G, Singh A, Goel B, Bhagat R. An Uncommon Cause of Postmenopausal Bleeding. J Midlife Health 2019; 10:213.</a></li><li><a class="nounderline abstract_t">Jones JS, Rossman L, Diegel R, et al. Sexual assault in postmenopausal women: epidemiology and patterns of genital injury. Am J Emerg Med 2009; 27:922.</a></li><li><a class="nounderline abstract_t">Poulos CA, Sheridan DJ. Genital injuries in postmenopausal women after sexual assault. J Elder Abuse Negl 2008; 20:323.</a></li><li><a class="nounderline abstract_t">Keller P, Lechner M. Injuries to the cervix in sexual assault victims. J Forensic Nurs 2010; 6:196.</a></li><li><a class="nounderline abstract_t">Gibson CJ, Huang AJ, McCaw B, et al. Associations of Intimate Partner Violence, Sexual Assault, and Posttraumatic Stress Disorder With Menopause Symptoms Among Midlife and Older Women. JAMA Intern Med 2019; 179:80.</a></li></ol></div><div id="topicVersionRevision">Topic 5421 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15763777" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical pathway for the evaluation of postmenopausal bleeding with an emphasis on endometrial cancer detection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14756741" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Frequency of spontaneously occurring postmenopausal bleeding in the general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12117397" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15386607" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : How thick is too thick? When endometrial thickness should prompt biopsy in postmenopausal women without vaginal bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24518153" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Differential effects of menopausal therapies on the endometrium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25897368" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Intra-cavitary uterine pathology in women with abnormal uterine bleeding: a prospective study of 1220 women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14664881" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11056310" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Identification of women at high risk of developing endometrial cancer on tamoxifen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12753939" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Pathophysiology of endometrial bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24735184" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Bleeding patterns during the menopausal transition in the multi-ethnic Study of Women's Health Across the Nation (SWAN): a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31834160" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Uterine fibroids in menopause and perimenopause.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31480288" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The Impact of Hormonal Replacement Treatment in Postmenopausal Women with Uterine Fibroids: A State-of-the-Art Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8633139" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Diffuse adenomyosis: comparison of endovaginal US and MR imaging with histopathologic correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20424279" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Age-related differential diagnosis of vaginal bleeding in postmenopausal women: a series of 3047 symptomatic postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20424280" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Women with recurrent postmenopausal bleeding should be re-investigated but are not more likely to have endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21145186" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Diagnostic evaluation of the endometrium in postmenopausal bleeding: an evidence-based approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24770103" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Insufficient endometrial biopsy results in women with abnormal uterine bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24680590" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Endometrial cancer in morbidly obese women: do racial disparities affect surgical or survival outcomes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30083701" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23909869" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Role of postmenopausal bleeding pattern and women's age in the prediction of endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24377427" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Investigation of women with postmenopausal uterine bleeding: clinical practice recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16287001" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Postmenopausal choriocarcinoma: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16263546" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Primary fallopian tube carcinoma - the experience of a UK cancer centre and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23062258" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : [Postmenopausal bleeding and dietary supplements: a possible causal relationship with hop- and soy-containing preparations].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18396257" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Adverse effects of phytoestrogens on reproductive health: a report of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15237003" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17270189" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Tuberculous endometritis presenting as postmenopausal bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17464596" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Postmenopausal vaginal bleeding caused by endometrial tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17541465" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Postmenopausal tuberculosis endometritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31942160" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : An Uncommon Cause of Postmenopausal Bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19857408" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Sexual assault in postmenopausal women: epidemiology and patterns of genital injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19042660" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Genital injuries in postmenopausal women after sexual assault.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21114761" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Injuries to the cervix in sexual assault victims.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30453319" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Associations of Intimate Partner Violence, Sexual Assault, and Posttraumatic Stress Disorder With Menopause Symptoms Among Midlife and Older Women.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
